News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

News

Scribe Inks CRISPR Gene-Editing Deal with Prevail

May 19, 2023

Bloomberg

Read Now

Press Release

Scribe Inks CRISPR Gene-Editing Deal with Prevail

May 19, 2023

Bloomberg

Read Now

News

Scribe signs another big pharma deal

May 19, 2023

Evaluate

Read Now

Press Release

Scribe signs another big pharma deal

May 19, 2023

Evaluate

Read Now

News

Lilly’s Prevail, Doudna’s Scribe Partner on Genetic Treatments for Neuro Diseases

May 17, 2023

BioSpace

Read Now

Press Release

Lilly’s Prevail, Doudna’s Scribe Partner on Genetic Treatments for Neuro Diseases

May 17, 2023

BioSpace

Read Now

News

Scribe and Prevail partner for CRISPR-based genetic medicines

May 17, 2023

Pharmaceutical Technology

Read Now

Press Release

Scribe and Prevail partner for CRISPR-based genetic medicines

May 17, 2023

Pharmaceutical Technology

Read Now

News

Scribe and Prevail to accelerate CRISPR-based genetic medicines for neurological and neuromuscular diseases

May 17, 2023

Labiotech

Read Now

Press Release

Scribe and Prevail to accelerate CRISPR-based genetic medicines for neurological and neuromuscular diseases

May 17, 2023

Labiotech

Read Now

News

Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

May 16, 2023

Read Now

Press Release

Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

May 16, 2023

Read Now

News

CRISPR technologies fuelling haematological innovations

April 12, 2024

European Pharmaceutical Review

Read Now

News

CRISPR drug licensing deals secure $21bn in top three therapy areas over five years

March 28, 2024

Pharmaceutical Technology

Read Now

News

Benjamin Oakes and the Promise of CRISPR

March 5, 2024

Sounds of Science

Read Now

News

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

Read Now

News

CRISPR by Design with Benjamin Oakes

February 20, 2024

Andreessen Horowitz

Read Now

News

CRISPR Partnerships Propel Precision Medicine

February 20, 2024

CRISPR Medicine News

Read Now

Press release

Scribe Therapeutics Announces Expansion of San Francisco Bay Area Headquarters, 3 Key Senior Hires

July 26, 2022

Read Now

Press release

Scribe Therapeutics to Participate in SVB Securities Biopharma Private Company Connect

July 15, 2022

Read Now

Press release

Scribe Therapeutics Expands Collaboration With Biogen to Second Target

May 2, 2022

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference

April 1, 2022

Read Now

Press release

Scribe Therapeutics Appoints David Parrot as Chief Financial Officer and George Manning as Controller

March 9, 2022

Read Now

Press release

Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines

March 31, 2021

Read Now

Publications

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publications

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publications

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publications

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publications

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publications

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publications

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publications

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now